<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00791544</url>
  </required_header>
  <id_info>
    <org_study_id>TED10630</org_study_id>
    <secondary_id>EudraCT 2008-000809-10</secondary_id>
    <nct_id>NCT00791544</nct_id>
  </id_info>
  <brief_title>Dose Finding Study of AVE1642 in Patients With Advanced or Metastatic Liver Carcinoma</brief_title>
  <official_title>Dose-finding, Safety, Pharmacokinetic and Pharmacodynamic Study of AVE1642, an Anti-Insulin-like Growth Factor-1 Receptor (IGF-1R/CD221) Monoclonal Antibody, Administered as Single Agent and in Combination With Other Anti Cancer Therapies (Sorafenib or Erlotinib) in Patients With Advanced Liver Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to select the dose of AVE1642 to be administered in
      patients with liver carcinoma not eligible for local treatment.

      The secondary objectives of the study are:

        -  To evaluate the safety profile of AVE1642 as single agent and the safety profile of
           combinations with other anti-cancer therapies of interest in liver carcinoma , including
           detection of immunogenicity.

        -  To evaluate pharmacokinetics and pharmacodynamics profiles of AVE1642 as single agent or
           any PK interactions when given in combination with other anti-cancer therapies.

        -  To assess the preliminary clinical activity in terms of response rate (Complete response
           + Partial response), duration of responses, stabilisation rate and duration of
           stabilisation, according to RECIST criteria.

        -  To assess the biological activity at the tumor level.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      AVE1642 will be administered as an IV infusion on day 1 and then every 3 weeks for at least 2
      infusions for evaluability requirements. Curative and / or prophylactic management of
      allergic reactions during infusion will be implemented when needed. The duration of the study
      for one patient will include a period for inclusion of up to 2 weeks, at least 2 cycles of
      treatment in dose escalation step (one cycle of AVE1642 alone and at least one cycle of
      AVE1642 in combination) and at least one cycle of the combination in the extension cohort,
      followed, when possible, by a minimum of 30-day follow-up after the last drug administration,
      in order to detect any potential immunogenicity. In the second step, the patients will
      continue treatment until disease progression, unacceptable toxicity or willingness to stop.

      The expected enrolment period is 15 months with at least 30 day follow-up after the last
      patient treated.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Company decision to discontinue the AVE1642 development program, not due to any safety or
    efficacy concerns
  </why_stopped>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">November 2009</completion_date>
  <primary_completion_date type="Actual">November 2009</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose-limiting toxicities (DLT) based on grade = or &gt; 3 hematological or non-hematological toxicity and on fasting hyperglycemia</measure>
    <time_frame>Cycle 1 and cycle 2 (6 weeks)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Anti tumoral activity</measure>
    <time_frame>Every 2 cycles</time_frame>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Liver Carcinoma</condition>
  <arm_group>
    <arm_group_label>Dose Level -1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.5 mg/kg AVE1642 single agent at cycle 1 with sorafenib at cycle 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Level 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 mg/kg AVE1642 single agent at cycle 1 with sorafenib at cycle 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Level 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 mg/kg AVE1642 single agent at cycle 1 with sorafenib at cycle 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Level 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 mg/kg AVE1642 single agent at cycle 1 with sorafenib at cycle 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Level 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>12 mg/kg AVE1642 single agent at cycle 1 with sorafenib at cycle 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Level 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>18 mg/kg AVE1642 single agent at cycle 1 with sorafenib at cycle 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combination cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AVE1642 selected dose in combination with sorafenib</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combination cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AVE1642 selected dose in combination with erlotinib</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AVE1642</intervention_name>
    <description>intravenous infusion</description>
    <arm_group_label>Dose Level -1</arm_group_label>
    <arm_group_label>Dose Level 1</arm_group_label>
    <arm_group_label>Dose Level 2</arm_group_label>
    <arm_group_label>Dose Level 3</arm_group_label>
    <arm_group_label>Dose Level 4</arm_group_label>
    <arm_group_label>Dose Level 5</arm_group_label>
    <arm_group_label>Combination cohort 1</arm_group_label>
    <arm_group_label>Combination cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sorafenib</intervention_name>
    <description>oral intake</description>
    <arm_group_label>Dose Level -1</arm_group_label>
    <arm_group_label>Dose Level 1</arm_group_label>
    <arm_group_label>Dose Level 2</arm_group_label>
    <arm_group_label>Dose Level 3</arm_group_label>
    <arm_group_label>Dose Level 4</arm_group_label>
    <arm_group_label>Dose Level 5</arm_group_label>
    <arm_group_label>Combination cohort 1</arm_group_label>
    <other_name>Nevaxar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>erlotinib</intervention_name>
    <description>oral intake</description>
    <arm_group_label>Combination cohort 2</arm_group_label>
    <other_name>Tarceva</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients not eligible for surgical resection, liver transplantation, local ablation
             techniques or chemoembolisation and with histologically proven liver carcinoma
             whenever possible or combination of radiologically documented hypervascular liver
             tumour and α foeto protein level ≥ 400 ng/ml

          -  Signed and dated approved patient informed consent form prior to enrollment into the
             study

        Exclusion Criteria:

          -  ECOG performance status &gt; 2

          -  Inadequate organ function:

               -  Neutrophils (ANC) &lt; 1,500/mm3

               -  Hemoglobin &lt; 10g/dl

               -  Platelets &lt; 100,000/mm3

               -  Total bilirubin &gt; 1.5 x ULN

               -  ASAT, ALAT &gt; 3 x ULN

               -  Creatininemia &gt; 1.5 x ULN (or ≥ 2.0 mg/dl)

               -  INR &gt; 1.6

               -  Liver cirrhosis Child Pugh B or C (score &gt; 6)

               -  HbA1C &gt; 8%

          -  No measurable or evaluable tumoral lesion

          -  Patients not eligible for sorafenib therapy and for whom this therapy cannot be
             postponed by 3 weeks (during AVE1642 single treatment period) in dose escalation part

          -  Prior exposure to an anti-IGF-1R class compound

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olivier Rosmorduc, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital St Antoine, 184 rue du Faubourg St Antoine, 75012 Paris - France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 13, 2008</study_first_submitted>
  <study_first_submitted_qc>November 13, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 14, 2008</study_first_posted>
  <last_update_submitted>August 3, 2010</last_update_submitted>
  <last_update_submitted_qc>August 3, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 4, 2010</last_update_posted>
  <responsible_party>
    <name_title>ICD Study Director</name_title>
    <organization>sanofi-aventis</organization>
  </responsible_party>
  <keyword>monoclonal antibody, anti IGF1R</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sorafenib</mesh_term>
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
    <mesh_term>Niacinamide</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

